BRPI0815681A2 - Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção. - Google Patents

Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção.

Info

Publication number
BRPI0815681A2
BRPI0815681A2 BRPI0815681-6A2A BRPI0815681A BRPI0815681A2 BR PI0815681 A2 BRPI0815681 A2 BR PI0815681A2 BR PI0815681 A BRPI0815681 A BR PI0815681A BR PI0815681 A2 BRPI0815681 A2 BR PI0815681A2
Authority
BR
Brazil
Prior art keywords
neuroprotection
treatment
methods
multiple system
system atrophy
Prior art date
Application number
BRPI0815681-6A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Hakan Eriksson
Werner Poewe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0815681A2 publication Critical patent/BRPI0815681A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0815681-6A2A 2007-08-23 2008-08-22 Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção. BRPI0815681A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95752507P 2007-08-23 2007-08-23
US95752307P 2007-08-23 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (1)

Publication Number Publication Date
BRPI0815681A2 true BRPI0815681A2 (pt) 2015-02-18

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815681-6A2A BRPI0815681A2 (pt) 2007-08-23 2008-08-22 Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção.

Country Status (25)

Country Link
US (6) US20090054468A1 (enExample)
EP (1) EP2200616B1 (enExample)
JP (2) JP5247804B2 (enExample)
KR (1) KR101588464B1 (enExample)
CN (4) CN105687199A (enExample)
AU (1) AU2008289653B2 (enExample)
BR (1) BRPI0815681A2 (enExample)
CA (1) CA2698205C (enExample)
CY (1) CY1113714T1 (enExample)
DK (1) DK2200616T3 (enExample)
EA (1) EA017510B1 (enExample)
ES (1) ES2399846T3 (enExample)
HR (1) HRP20130139T1 (enExample)
IL (2) IL203738A (enExample)
ME (1) ME01510B (enExample)
MX (1) MX2010001983A (enExample)
MY (1) MY155633A (enExample)
NZ (1) NZ584135A (enExample)
PH (1) PH12014501180A1 (enExample)
PL (1) PL2200616T3 (enExample)
PT (1) PT2200616E (enExample)
RS (1) RS52665B (enExample)
SI (1) SI2200616T1 (enExample)
WO (1) WO2009025618A1 (enExample)
ZA (1) ZA201000848B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
ES2587954T3 (es) * 2012-03-29 2016-10-27 Basf Se Compuestos de hetero-bicíclicos N-sustituidos y derivados para combatir plagas animales II
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
CR20170498A (es) 2015-05-05 2018-01-26 Pfizer 2-tiopirimidinonas
CA3067591A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
IL272043B (en) * 2017-07-17 2022-09-01 Astrazeneca Ab mpo inhibitors for use in medicine
AU2020363903A1 (en) * 2019-10-10 2022-03-24 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
AU2021230370A1 (en) * 2020-03-05 2022-10-20 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
WO2021226161A1 (en) * 2020-05-06 2021-11-11 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
JP2025528217A (ja) 2022-08-18 2025-08-26 アストラゼネカ・アクチエボラーグ ミエロペルオキシダーゼの阻害剤
CA3266275A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab PHARMACEUTICAL FORMULATION
EP4624473A1 (en) * 2022-12-09 2025-10-01 Shenzhen Salubris Pharmaceuticals Co., Ltd. Pyrrolo[3,2-d]pyrimidin-4-one derivative, and preparation method therefor and medical use thereof
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264210T3 (es) * 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
KR20150080013A (ko) * 2002-01-28 2015-07-08 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료용 조성물
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
EP2029603A1 (en) * 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
CN105687199A (zh) 2016-06-22
AU2008289653B2 (en) 2012-06-28
KR101588464B1 (ko) 2016-01-25
US20090054468A1 (en) 2009-02-26
HRP20130139T1 (hr) 2013-03-31
US20110207755A1 (en) 2011-08-25
CY1113714T1 (el) 2016-06-22
HK1145141A1 (en) 2011-04-08
US20200405724A1 (en) 2020-12-31
EP2200616B1 (en) 2012-12-26
MY155633A (en) 2015-11-13
CA2698205A1 (en) 2009-02-26
CA2698205C (en) 2016-06-21
AU2008289653A1 (en) 2009-02-26
ZA201000848B (en) 2012-07-25
IL203738A (en) 2015-08-31
ME01510B (me) 2014-04-20
MX2010001983A (es) 2010-03-10
JP2010536849A (ja) 2010-12-02
CN113633641A (zh) 2021-11-12
US10772890B2 (en) 2020-09-15
JP2013151547A (ja) 2013-08-08
CN101873857A (zh) 2010-10-27
CN103638029A (zh) 2014-03-19
EP2200616A4 (en) 2010-08-25
DK2200616T3 (da) 2013-03-04
US20130059870A1 (en) 2013-03-07
EP2200616A1 (en) 2010-06-30
IL240130A0 (en) 2015-09-24
WO2009025618A1 (en) 2009-02-26
RS52665B (sr) 2013-06-28
EA201000202A1 (ru) 2010-10-29
NZ584135A (en) 2012-04-27
US20190099423A1 (en) 2019-04-04
SI2200616T1 (sl) 2013-03-29
US20140221400A1 (en) 2014-08-07
EA017510B1 (ru) 2013-01-30
PT2200616E (pt) 2013-02-27
KR20100055434A (ko) 2010-05-26
JP5247804B2 (ja) 2013-07-24
ES2399846T3 (es) 2013-04-03
PL2200616T3 (pl) 2013-04-30
PH12014501180A1 (en) 2015-08-24

Similar Documents

Publication Publication Date Title
BRPI0815681A2 (pt) Uso de um inibidor de mieloperoxidase, métodos para o tratamento de atrofia sistema múltipla, e da doença de huntington, e, método para neuroproteção.
BRPI0717480A2 (pt) Método e sistema para tratamento de um alimentação de hidrocarboneto, e, composição de hidrocarboneto.
BRPI0720349A2 (pt) Método para operar um instrumento acoplado com um sistema microcirúrgico.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0911078A2 (pt) sistema e método para a projetar e formar um implante cirúrgico
NL2003118A1 (nl) Alignment system, lithographic system and method.
BRPI0819127A2 (pt) Método para cimentar.
BRPI0811883A2 (pt) Método e sistema para planejamento dentário.
BRPI0817872A2 (pt) sistema para tratamento de um paciente que apresenta um distúrbio intestinal.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0810356A2 (pt) Sistema de aquecimento para uma formação de subsuperfície, e, método para aquecer uma formação de subsuperfície.
BRPI0813146A2 (pt) Método para operar uma instalação de gado, método para controlar gado, e, sistema de processamento de gado
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI0811048A2 (pt) Sistema e método para criar uma lista de informações compartilhadas em uma rede não-herárquica.
BRPI0819842A2 (pt) Sistema de carga e método para operar o mesmo.
BRPI0815707A2 (pt) Processo para a liquefação de uma corrente gasosa, e, sistema para o tratamento de uma corrente de alimentação gasosa.
BRPI0716172A2 (pt) instalaÇço de remoÇço de revestimento e mÉtodo para operaÇço da mesma.
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0907054A2 (pt) sistema de aeronave, e, método para operar um sistema de aeronave
BRPI0812508A2 (pt) Dispositivo e processo para controlar um dispositivo de freio.
BRPI0823030A2 (pt) Sistema de elevador, e, método para fazer um sistema de elevador.
BRPI0811113A2 (pt) Processo, aparelho e sistema para estabelecer conexão.
BRPI0808030A2 (pt) Método para desobstruir um tubo de conteúdos com um sistema pneumático, e, sistema de desobstrução para um tubo.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0817328A2 (pt) Método e aparelho para tratamento de resíduo orgânico.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]